Blood Collection Devices Market to Reach $15.88 Billion by 2034 as Chronic Disease Testing Surges
核心洞察
The global blood collection devices (搜索) market is projected to grow from $7.85 billion in 2024 to approximately $15.88 billion by 2034, a CAGR of 7.3%.
Needles and syringes led product segments in 2024 with over 38.5% share, while diagnostic applications accounted for more than 65.3% of the market.
North America held the largest regional position in 2024 with over 35.6% share, valued at nearly $2.79 billion on high testing volumes.
The global blood collection devices (搜索) market is on track to nearly double over the next decade, expanding from US$ 7.85 billion in 2024 to approximately US$ 15.88 billion by 2034 at a compound annual growth rate of 7.3% during the 2025–2034 forecast period, according to new market analysis. Growth is being driven by rising diagnostic testing volumes, a growing chronic disease burden, and accelerating adoption of safety-engineered sampling technologies across hospitals, diagnostic laboratories, blood banks, and research centers.
Blood collection devices (搜索) — including needles, blood collection tubes, lancets, syringes, and vacuum blood collection systems (搜索) — underpin routine clinical decision-making. The World Health Organization (WHO) estimates that laboratory testing influences nearly 70% of medical decisions, underscoring the importance of reliable specimen collection as testing demand rises.
Chronic Disease Burden Anchors Demand
The expanding diabetes (搜索) and cancer (搜索) populations are central to the market's trajectory. According to the International Diabetes Federation (搜索) (IDF), approximately 537 million adults worldwide were living with diabetes in 2021, a figure projected to reach 643 million by 2030 and 783 million by 2045 — growth of nearly 46% from 2021 levels. Frequent glucose monitoring and routine blood testing in this population directly support demand for lancets and blood sampling devices.
Cancer (搜索) diagnostics are contributing additional volume. WHO reported approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, increasing requirements for blood-based diagnostic tests and biomarker analysis.
In the United States, the Centers for Disease Control and Prevention (搜索) (CDC) estimates that approximately 38.4 million Americans were living with diabetes (搜索), representing 11.6% of the population and requiring regular monitoring and laboratory testing.
Safety Concerns Reshape Product Adoption
Occupational safety is emerging as a defining trend. The CDC estimates that approximately 385,000 needlestick and sharps-related injuries occur annually among hospital healthcare workers in the United States, encouraging adoption of safety-engineered needles, retractable syringes, and closed blood collection systems. WHO notes that safety-engineered devices can lower blood exposure risks.
Vacuum tube blood collection systems are also gaining acceptance because they reduce direct blood exposure and allow multiple samples from a single venipuncture. WHO guidelines indicate that vacuum systems improve safety compared with traditional needle-and-syringe methods, and these systems are increasingly used in hospitals and diagnostic laboratories requiring efficient sample handling.
Additional momentum comes from capillary blood collection devices (搜索) using micro-needles and small-volume sampling, which support home monitoring and point-of-care diagnostics. The FDA classifies capillary blood collection devices as medical devices used for collecting and transporting whole blood specimens for clinical analysis.
Segment and Regional Performance
Needles and syringes dominated the product segment in 2024, accounting for more than 38.5% market share, supported by widespread use in hospitals, diagnostic centers, and healthcare facilities. Manual blood collection methods held a leading position in the method segment with over 67.2% share, attributed to cost-effectiveness and extensive adoption across healthcare settings.
By application, diagnostics represented the largest segment in 2024, contributing more than 65.3% of market share, driven by increasing demand for blood-based testing and disease detection. Diagnostic end-users accounted for the highest share at more than 34.3%, reflecting growing utilization of clinical laboratories for routine and specialized testing.
North America maintained its leading regional position in 2024, holding more than 35.6% share with an estimated market value of nearly US$ 2.79 billion. The region's position is supported by advanced healthcare infrastructure and high testing volumes; U.S. national health expenditure reached US$ 4.9 trillion in 2023, accounting for 17.6% of GDP. A mature clinical laboratory network and strict healthcare safety regulations further strengthen adoption of advanced collection devices designed to reduce occupational risks.
Blood Donation Infrastructure Adds Volume
Transfusion services represent a substantial and recurring source of device consumption. India requires approximately 14.6 million blood units annually and collected 14,601,147 units during 2024–25, compared with 12,695,363 units in 2023 — an increase of roughly 1.9 million units, or 15% year-on-year. A national clinical modelling study estimated India's annual whole blood requirement at approximately 14.6 million units (95% CI: 14.59–14.62 million), equivalent to around 36.3 blood donations per 1,000 population.
Each whole blood donation generally requires one blood collection bag, a sterile donor needle assembly, and multiple testing sample tubes. Based on India's annual collection volume, transfusion services may require an estimated 44–73 million collection-related disposable components annually, excluding diagnostic blood testing procedures.
India's licensed blood bank network has expanded alongside collection volumes, reaching 4,153 licensed blood banks and blood centers as of November 30, 2023, up from 2,760 in 2015. Historical government statistics show collection rising from approximately 9.94 million units in 2013–14 to 11.09 million units in 2016–17, growth of about 1.15 million units, or nearly 12%.
Clinical demand in the country is shaped by anemia (搜索), maternal health conditions, trauma, surgery, cancer (搜索), and chronic diseases. Research cited in the analysis indicates that approximately 45–50% of blood utilization is associated with anemia and obstetric cases, while around 15–20% is linked with trauma and surgical requirements.
Screening Requirements Sustain Consumable Use
Blood safety testing requirements add a further layer of demand. The CDC reports that every blood donation undergoes testing for infectious markers, including HIV (搜索), hepatitis B (搜索), and hepatitis C (搜索), increasing the need for standardized collection tubes, bags, and sampling devices. WHO monitors global blood systems across 168 countries, focusing on collection, testing, processing, and availability of safe blood products.
Beyond transfusion, blood samples are increasingly used in genetic testing, biomarker discovery, and personalized medicine research, with the FDA regulating blood specimen collection devices used for DNA testing and laboratory analysis. The growth of molecular diagnostics is creating demand for specialized collection tubes and specimen preservation technologies.
Modern laboratories are also prioritizing sample accuracy, traceability, and contamination prevention. The CDC emphasizes that proper blood collection practices are essential because inaccurate samples can delay diagnosis and treatment, a consideration driving design of collection devices compatible with automated laboratory workflows and quality management systems.